DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased substantially, both for the quarter and year to date. However, due to the current product mix, gross margins decreased resulting in a slightly larger net loss for the quarter. Some of the results highlighted by the report are as follows: